Kening Li, Ph.D. has over two decades of experience practicing intellectual property and commercial law in the U.S. and China.
Dr. Li assists clients ranging from start-up to Fortune 500 companies in managing IP assets as an integral part of their comprehensive competition strategy. He is experienced in formulating overall IP strategy; leveraging IP assets in investment transactions; enforcing IP rights in courts and administrative agencies; resolving difficult freedom-to-operate obstacles; negotiating licensing agreements; and effectively utilizing existing intellectual property portfolio to strengthen a client’s competitive positions.
In China, he and his team members advise multinational companies on business and IP strategies, including patent and trademark filing, oppositions and enforcement, IP due diligence and FTO analysis, licensing arrangements, research and collaboration agreements, and IP enforcement and litigation.
Dr. Li’s unique understanding of the way government operates in China has allowed him to offer valuable services to western companies starting or expanding their business operations in China.
Dr. Li has also advised clients with regard to China’s data privacy and data protection laws and regulations and to e-commerce related IP issues, including news aggregator liability, as well as online anti-counterfeiting campaigns.
Dr. Li is a member of the American Bar Association, the License Executives Society, the American Association for the Advancement of Sciences and the Chinese Intellectual Property Law Society.
• Duane Morris & Selvam LLP/ Duane Morris LLP
- Director/Partner, 2017-present
• Miller Canfield
- Chief of IP, China, 2014-2017
• Pinsent Masons LLP
- Partner, 2008-2014
• “From Seed Stealing to the Economic Espionage Act,” WeChat Public Account Publication, April 5, 2016
• “Mechanisms for successful University Technology Transfer in the U.S.,” Science Daily, June 21, 2015
• “China IP Developments and Trends 2014,” Business Insights 2014, British Chamber of Commerce Shanghai
• “Protect your IP in China Before Somebody Else Does,” Business in China Supplement to Sunday Telegraph, 2009
• “China’s New Strategy Puts Intellectual Property First,” Out-Law.com, 22 October 2009
• “Beijing Ruling Shows Why Foreign Companies Need a Patent Strategy for China,” Out-Law.com, 26 August 2009
• Co-author, “The Practical Effect of the KSR Decision,” August 19, 2007
• “How to Protect Trade Secrets,” China Business Review, No. 3, 2005, pp. 36-41
Selected Speaking Engagements
• Panel Chair, "Top 10 IP Issues in Asia Pacific," The Association of Corporate Patent Counsel Summer Conference, Utah, June 2017
• “Intellectual Property Related Issues in ANDA Filings,” lecture to MBA students at the Yeehong Business School of Shenyang Pharmaceutical University, Beijing, June 2016
• Panel Chair, “IP and Regulatory Issues for International Bio-pharma Collaborations,” Chinese Biopharmaceutical Association Annual Meeting, Tsingtao, China, July 2012
• Speaker and Moderator, University of Wisconsin Conference on Innovation (co-sponsored by Shanghai Minhang District Government), Shanghai, China, June 2012
• Panel Chair, "IP Commercialization and Technology Transfer," China International IP Forum and Innovation Exhibition, China Medical City, Taizhou, China, May 2012
• Panel Chair, “IP Protection in China,” BIO CEO Delegation, Shanghai, China, 2011
• Speaker, “IP Protection,” US-China Green Energy Council Conference, China, 2010
• Panelist, “Building a Global Patent Portfolio and Protecting Your IP in China,” ChinaBio Partnering Forum, Shanghai, 2009
• Co-chair of discussion, “Intellectual Property, Legal & Regulatory Issues,” the First Pearl River International Biopharmaceutical Forum & 14th Chinese Pharmaceutical Association Annual Conference, China, 2009
• Speaker, “IP Policy Developments in the U.S. – Recent Significant U.S. Supreme Court Patent Cases,” Program in Intellectual Property Management: from the Lab to the Market, Nanjing University, China, 2008
• Speaker, “How Multinational Companies Protect and Leverage Intellectual Property Rights,” International Drug Discovery Science & Technology Conference, China, 2006• Chair of discussion, “Why Did China Invalidate the Viagra Patent and What Is Pfizer to Do?” Biotechnology Industry Organization's Annual International Convention (BIO 2005), Philadelphia, Pennsylvania, 2005
Professional Activities; •American Bar Association; •Chinese Bio-Pharmaceutical Association, General Counsel; •AmCham Shanghai; •Chinese Intellectual Property Association